Legacy Bridge’s NovoCure NVCR Stock Holding History

Legacy Bridge’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-400	Closed	-$6.25K	–	311
2024 Q1	$6.25K	Hold	400	–	–	﹤0.01%	287
2023 Q4	$5.97K	Sell	400 -75	-16%	-$1K	﹤0.01%	267
2023 Q3	$7.67K	Sell	475 -75	-14%	-$2.16K	0.01%	259
2023 Q2	$22.8K	Hold	550	–	–	0.02%	224
2023 Q1	$33.1K	Hold	550	–	–	0.02%	209
2022 Q4	$40.3K	Hold	550	–	–	0.03%	201
2022 Q3	$42K	Hold	550	–	–	0.03%	190
2022 Q2	$38K	Hold	550	–	–	0.03%	200
2022 Q1	$46K	Hold	550	–	–	0.03%	199
2021 Q4	$41K	Hold	550	–	–	0.02%	209
2021 Q3	$64K	Hold	550	–	–	0.04%	191
2021 Q2	$122K	Hold	550	–	–	0.07%	167
2021 Q1	$73K	Hold	550	–	–	0.05%	183
2020 Q4	$95K	Hold	550	–	–	0.07%	165
2020 Q3	$61K	Hold	550	–	–	0.06%	175
2020 Q2	$33K	Hold	550	–	–	0.04%	192
2020 Q1	$37K	Buy	550 +90	+20%	+$7.11K	0.05%	173
2019 Q4	$39K	Hold	460	–	–	0.03%	191
2019 Q3	$34K	Buy	460 +400	+667%	+$32K	0.03%	194
2019 Q2	$4K	Buy	+60	New	+$3.04K	﹤0.01%	293

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Legacy Bridge's NVCR Position: Q2 2024 in Review

Legacy Bridge sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 400 shares — an estimated $6.25K sold.

Legacy Bridge first reported a position in NVCR in Q2 2019 and held it in 20 quarters. The position peaked at $122K in Q2 2021. 236 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

Legacy Bridge reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
Legacy Bridge sold 400 NovoCure shares in Q2 2024, an estimated $6.25K.
Legacy Bridge first reported a position in NovoCure in Q2 2019 and held it in 20 quarters.
Legacy Bridge's NovoCure position peaked at $122K in Q2 2021.
236 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on Legacy Bridge's 13F filing for Q2 2024, filed 6 Aug 2024.